



## Karuna Therapeutics to Present at Upcoming Investor Conferences

March 10, 2022

BOSTON--(BUSINESS WIRE)--Mar. 10, 2022-- Karuna Therapeutics, Inc. (NASDAQ: KRTX), a clinical-stage biopharmaceutical company driven to create and deliver transformative medicines for people living with psychiatric and neurological conditions, today announced that senior management will present at the following upcoming virtual investor conferences:

### **Oppenheimer 32<sup>nd</sup> Annual Healthcare Conference**

Date: Tuesday, March 15, 2022

Time: 9:20 a.m. ET

### **1<sup>st</sup> Annual Needham Virtual Neuroscience Forum**

Date: Wednesday, March 16, 2022

Time: 11:00 a.m. ET

### **Stifel 2022 CNS Days**

Date: Monday, March 28, 2022

Time: 1:30 p.m. ET

A live webcast of the presentations will be available on the Investor Relations page of Karuna's website at [investors.karunatx.com](https://investors.karunatx.com). A replay of the webcasts will also be archived for up to 30 days on Karuna's website following the conference.

### **About Karuna Therapeutics**

Karuna Therapeutics is a clinical-stage biopharmaceutical company driven to create and deliver transformative medicines for people living with psychiatric and neurological conditions. At Karuna, we understand there is a need for differentiated and more effective treatments that can help patients navigate the challenges presented by these severe and disabling disorders. Utilizing our extensive knowledge of neuroscience, we are harnessing the untapped potential of the brain in pursuit of novel pathways to develop medicines that make meaningful differences in peoples' lives. For more information, please visit [www.karunatx.com](https://www.karunatx.com).

View source version on [businesswire.com](https://www.businesswire.com/news/home/20220310005081/en/): <https://www.businesswire.com/news/home/20220310005081/en/>

### **Investors:**

Alexis Smith

518-338-8990

[asmith@karunatx.com](mailto:asmith@karunatx.com)

### **Media:**

Lauren Sneider

917-886-0247

[lsneider@karunatx.com](mailto:lsneider@karunatx.com)

Source: Karuna Therapeutics, Inc.